You are here

  • Home
  • Archive
  • Volume 68, Issue 4
  • Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

Article metrics

Article menu

Download PDFPDF

XML
Hepatology
Original article
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

 

Online download statistics by month:

Online download statistics by month: April 2018 to March 2024

AbstractFullPdf
Apr 2018751761303
May 201824328984
Jun 201820120854
Jul 201815615648
Aug 201811011061
Sep 201811511444
Oct 201816716753
Nov 201823623961
Dec 201842846957
Jan 201921821859
Feb 201922121797
Mar 2019403395160
Apr 2019146141102
May 201914514191
Jun 201914213093
Jul 2019143116125
Aug 2019125110115
Sep 2019210192125
Oct 201917615243
Nov 20191009726
Dec 201910510136
Jan 20201049428
Feb 20201049635
Mar 20201244123818
Apr 202014113511
May 2020957016
Jun 2020897824
Jul 2020635730
Aug 202052468
Sep 202042389
Oct 2020615025
Nov 2020413621
Dec 2020797034
Jan 2021635332
Feb 2021727022
Mar 2021674923
Apr 202151479
May 2021585119
Jun 202129289
Jul 2021282719
Aug 2021312510
Sep 2021302514
Oct 2021524838
Nov 2021413832
Dec 2021503515
Jan 2022504918
Feb 2022353516
Mar 2022596015
Apr 2022716324
May 2022585218
Jun 2022454315
Jul 2022554717
Aug 2022565222
Sep 2022474526
Oct 2022525112
Nov 2022665327
Dec 2022554820
Jan 2023494519
Feb 2023928621
Mar 2023565511
Apr 2023424326
May 2023767224
Jun 2023474713
Jul 2023655522
Aug 2023353222
Sep 202342416
Oct 2023656512
Nov 2023817512
Dec 2023534610
Jan 2024625216
Feb 2024484413
Mar 2024646018
Total875484432813